RPD.F ROYALTY PHARMA OA DL-0001

Healthcare Biotechnology Frankfurt Exchange
78.89 EUR
Close of Nov 12, 2026
31.08 62.36
Market cap
EUR 35.1B
P/E
46.3x
P/B
4.45x
ROE
8.9%
Dividend yield
1.39%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RPD.F undervalued?

Graham number

The Graham number of ROYALTY PHARMA OA DL-0001 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ROYALTY PHARMA OA DL-0001 fundamental analysis

No fundamental analysis for ROYALTY PHARMA OA DL-0001 yet.

ROYALTY PHARMA OA DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ROYALTY PHARMA OA DL-0001

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance t…

Full company profile